Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia

NCT04964557 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04964557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04964557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2021
Completion date
July 15, 2022
Enrollment
411 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidaemia